Profile data is unavailable for this security.
About the company
ResMed Inc. is a holding company. The Company, through its subsidiaries, in the development, manufacturing, distribution and marketing of medical devices and cloud-based software applications that diagnose, treat and manage respiratory disorders, including sleep disordered breathing (SDB), chronic obstructive pulmonary disease, neuromuscular disease and other chronic diseases. It also operates a Software as a Service (SaaS) business in the United States and Germany that includes out-of-hospital software platforms designed to support the professionals and caregivers who help people stay healthy in the home or care setting of their choice. The Company’s segments include Sleep and Respiratory Care and SaaS. Its products and solutions are designed to improve patients' quality of life and reduce the impact of chronic disease. Its cloud-based digital health software applications, along with its devices, are designed to provide connected care to improve patient outcomes.
- Revenue in USD (TTM)4.81bn
- Net income in USD1.11bn
- Incorporated1994
- Employees9.98k
- LocationResmed Inc9001 Spectrum Center BlvdSAN DIEGO 92123-1438United StatesUSA
- Phone+1 (858) 746-2400
- Fax+1 (302) 636-5454
- Websitehttps://www.resmed.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cooper Companies Inc | 3.80bn | 359.30m | 19.73bn | 15.00k | 55.18 | 2.49 | 26.81 | 5.19 | 1.80 | 1.80 | 19.02 | 39.80 | 0.3196 | 1.70 | 5.56 | 253,606.70 | 3.02 | 10.06 | 3.29 | 11.34 | 66.36 | 65.54 | 9.45 | 29.00 | 1.18 | 5.46 | 0.2493 | 0.3469 | 8.61 | 7.24 | -23.74 | -3.66 | 15.18 | 0.00 |
| Illumina Inc | 4.39bn | -1.58bn | 20.88bn | 10.59k | -- | 9.85 | -- | 4.76 | -10.00 | -10.00 | 27.61 | 13.36 | 0.5441 | 2.66 | 6.17 | 414,542.00 | -19.63 | -6.20 | -23.16 | -7.28 | 63.94 | 66.39 | -36.08 | -15.48 | 1.85 | 38.44 | 0.4834 | -- | -1.75 | 6.21 | 73.64 | -- | -7.91 | -- |
| Steris PLC | 5.12bn | 602.62m | 20.95bn | 18.18k | 34.93 | 3.18 | 18.92 | 4.09 | 6.08 | 4.38 | 51.62 | 66.80 | 0.4758 | 3.86 | 5.49 | 281,655.40 | 5.62 | 5.19 | 6.10 | 5.68 | 43.01 | 43.64 | 11.81 | 10.97 | 1.55 | 8.29 | 0.2528 | 36.56 | 13.28 | 13.06 | -1.07 | 12.67 | 13.69 | 8.83 |
| Waters Corp | 2.91bn | 622.64m | 21.24bn | 7.90k | 34.14 | 13.25 | 26.07 | 7.31 | 10.48 | 10.48 | 48.89 | 27.00 | 0.645 | 2.20 | 4.47 | 367,740.10 | 13.82 | 19.77 | 16.72 | 25.29 | 59.73 | 58.45 | 21.43 | 23.38 | 1.38 | 10.11 | 0.5325 | 0.00 | -0.5229 | 4.09 | -9.26 | 1.53 | 4.72 | -- |
| Zimmer Biomet Holdings Inc | 7.60bn | 1.08bn | 21.75bn | 18.00k | 20.81 | 1.76 | 10.57 | 2.86 | 5.25 | 5.25 | 36.87 | 62.00 | 0.3538 | 0.9136 | 5.38 | 421,972.20 | 5.05 | 2.21 | 5.82 | 2.52 | 71.78 | 71.25 | 14.28 | 7.28 | 0.6987 | 7.52 | 0.3425 | 38.90 | 6.55 | -1.40 | 252.86 | -- | 9.44 | 0.00 |
| West Pharmaceutical Services Inc. | 2.88bn | 499.60m | 22.57bn | 10.60k | 46.18 | 8.21 | 35.59 | 7.85 | 6.75 | 6.75 | 38.86 | 37.96 | 0.7743 | 4.50 | 5.51 | 271,358.50 | 13.02 | 15.61 | 15.16 | 18.65 | 34.87 | 38.06 | 16.81 | 18.47 | 2.23 | -- | 0.0695 | 10.69 | 2.18 | 11.43 | 2.28 | 23.76 | 28.16 | 6.20 |
| DexCom Inc | 3.95bn | 680.80m | 29.39bn | 9.60k | 45.93 | 14.85 | 32.90 | 7.43 | 1.64 | 1.64 | 9.52 | 5.07 | 0.6107 | 2.76 | 4.42 | 411,875.00 | 10.51 | 8.30 | 14.28 | 10.50 | 62.10 | 65.90 | 17.22 | 14.14 | 2.12 | -- | 0.5579 | 0.00 | 24.49 | 28.56 | 58.70 | -- | 28.66 | -- |
| Veeva Systems Inc | 2.57bn | 615.26m | 34.11bn | 7.17k | 54.65 | 6.57 | 52.33 | 13.25 | 3.85 | 3.85 | 15.69 | 32.04 | 0.4453 | -- | 6.27 | 358,846.80 | 10.65 | 11.97 | 12.97 | 15.36 | 73.35 | 72.00 | 23.91 | 23.74 | -- | -- | 0.00 | 0.00 | 9.68 | 22.35 | 7.79 | 18.00 | 21.68 | -- |
| IDEXX Laboratories, Inc. | 3.84bn | 866.24m | 34.28bn | 11.00k | 40.39 | 21.22 | 34.55 | 8.92 | 10.36 | 10.36 | 46.00 | 19.72 | 1.19 | 3.85 | 7.14 | 349,528.80 | 26.91 | 28.00 | 38.86 | 43.49 | 60.72 | 58.74 | 22.53 | 21.35 | 1.03 | 59.10 | 0.3507 | 0.00 | 8.72 | 10.59 | 24.44 | 17.39 | 1.68 | -- |
| Resmed Inc | 4.81bn | 1.11bn | 35.46bn | 9.98k | 32.02 | 6.82 | 27.50 | 7.38 | 7.54 | 7.54 | 32.59 | 35.39 | 0.6886 | 2.17 | 6.08 | 481,711.90 | 15.94 | 14.24 | 18.11 | 16.53 | 57.67 | 56.85 | 23.15 | 20.35 | 1.91 | 44.71 | 0.1154 | 32.62 | 10.95 | 12.44 | 13.75 | 19.98 | 8.23 | 5.34 |
| Agilent Technologies Inc | 6.50bn | 1.41bn | 36.94bn | 17.40k | 26.74 | 6.26 | 22.21 | 5.69 | 4.81 | 4.81 | 22.14 | 20.53 | 0.5996 | 2.87 | 5.06 | 358,950.30 | 13.04 | 11.00 | 16.13 | 13.25 | 54.75 | 53.29 | 21.75 | 18.01 | 1.37 | 55.86 | 0.3319 | 21.46 | -0.219 | 6.82 | -1.12 | 7.39 | 10.98 | 8.86 |
| GE HealthCare Technologies Inc | 19.56bn | 1.68bn | 38.79bn | 51.00k | 23.25 | 4.66 | 16.77 | 1.98 | 3.65 | 3.65 | 42.63 | 18.20 | 0.5906 | 5.40 | 4.41 | 383,490.20 | 5.22 | -- | 6.97 | -- | 41.33 | -- | 8.84 | -- | 0.982 | 5.67 | 0.5478 | -- | 6.60 | -- | -26.82 | -- | -- | -- |
| Edwards Lifesciences Corp | 5.62bn | 1.43bn | 41.01bn | 19.80k | 29.37 | 4.30 | 26.26 | 7.30 | 2.37 | 6.93 | 9.32 | 16.18 | 0.5032 | 1.12 | 7.72 | 283,904.00 | 12.76 | 16.63 | 14.98 | 19.12 | 78.63 | 76.71 | 25.35 | 24.84 | 2.89 | -- | 0.0585 | 0.00 | 11.56 | 10.03 | -7.85 | 13.70 | 1.96 | -- |
| Cencora Inc | 293.96bn | 1.51bn | 47.92bn | 42.00k | 32.40 | 60.91 | 18.18 | 0.163 | 7.51 | 7.51 | 1,467.70 | 3.99 | 4.53 | 15.59 | 12.44 | -- | 2.34 | 1.12 | 11.51 | 4.83 | 3.35 | 3.25 | 0.5168 | 0.2556 | 0.5291 | 19.37 | 0.848 | 65.38 | 12.12 | 10.36 | -13.53 | 13.02 | 9.45 | 4.98 |
Data as of Nov 21 2024. Currency figures normalised to Resmed Inc's reporting currency: US Dollar USD
32.93%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 30 Sep 2024 | 17.36m | 11.83% |
| BlackRock Fund Advisorsas of 30 Sep 2024 | 8.80m | 6.00% |
| SSgA Funds Management, Inc.as of 30 Sep 2024 | 6.26m | 4.27% |
| Walter Scott & Partners Ltd.as of 30 Sep 2024 | 4.66m | 3.17% |
| Geode Capital Management LLCas of 30 Sep 2024 | 3.86m | 2.63% |
| Morgan Stanley & Co. LLCas of 30 Sep 2024 | 3.14m | 2.14% |
| Northern Trust Investments, Inc.(Investment Management)as of 30 Sep 2024 | 1.35m | 0.92% |
| BlackRock Advisors (UK) Ltd.as of 30 Sep 2024 | 1.03m | 0.70% |
| Invesco Advisers, Inc.as of 30 Sep 2024 | 961.34k | 0.66% |
| Charles Schwab Investment Management, Inc.as of 30 Sep 2024 | 924.05k | 0.63% |
More ▼
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
